Formosa Pharmaceuticals News

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), hassuccessfully completed a Series C financing round, increasing its cash capital by NTD $600million (approx. USD $21.1 million). In addition to the continuous support from major shareholder, Formosa Laboratories, numerousprominent venture capital firms participated in this round of capital increase, including ChinaDevelopment

Read More »

APP13007 completes Phase 2 clinical trial and EOP2 meeting.

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. The End-of-Phase 2 meeting with the FDA is successful, setting the stage for pivotal Phase 3 trials to begin as early as 2020-Q4. APP13007 meets primary endpoints demonstrating rapid

Read More »

Development Pipeline

Scroll to Top